Head of Respiratory Scientific Affairs, Viatris

Liz first joined Pfizer as part of her undergraduate degree program, working in early product development. Upon completion of her Bachelors and Ph.D. degrees, she re-joined Pfizer as a formulation lead for the Biologics group and led a team developing mAb formulations for early studies before progressing into respiratory development and then into a broader spectrum of dosage form development. Since that time, Liz has held a number of scientific leadership positions across the pharmaceutical sciences as a drug product SME, project team leader and people manager. In early 2021, Liz progressed into an Executive Director role with matrix accountability for the pharmaceutical sciences business in the anti-infective category. This included leading the pharmaceutical development of Paxlovid™ (Covid anti-viral).

In addition to these portfolio responsibilities, until recently Liz led the global pharmaceutical sciences (PSSM) EDI Council, has led many site initiatives, specifically around skills and early careers and was the lead pharmaceutical sciences colleague on the Sandwich site. During this time, she to represented Pfizer on Medicines Manufacturing LT and ABPI on the board of Cogent Skills. Upon the recent withdrawal of laboratory and clinical operations from the Sandwich site, Liz spent 9 months on secondment to the Office for Life Sciences as a Life Sciences expert and has recently started a new position as Head of Respiratory Scientific Affairs for Viatris based at the Sandwich site in the UK.

Liz has a BSc from Loughborough University in Medicinal and Pharmaceutical Chemistry, and a Ph.D. from the Welsh School of Pharmacy in Non-viral Gene Delivery to the Lung.